-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is a phenomenon in which breast epithelial cells proliferate out of control under the action of a variety of carcinogenic factors.
Breast cancer adenocarcinoma is often called the "pink killer", and its incidence ranks first among female malignancies, and male breast cancer is relatively rare.
Currently, most women with hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer (MBC) recommend single-dose endocrine therapy (ET).
In the past decade, new targeted therapies, mainly CDK4/6 inhibitors, combined with ET have significantly improved the progression-free survival (PFS) and overall survival (OS) of MBC patients.
In the past decade, new targeted therapies, mainly CDK4/6 inhibitors, combined with ET have significantly improved the progression-free survival (PFS) and overall survival (OS) of MBC patients.
Although Palocoxib combined with endocrine therapy is the standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer.
The trial is the PEARL trial, a multi-center, three-phase randomized study in which MBC patients with aromatase inhibitor resistance (AIs) are included in two consecutive cohorts.
After the discovery of new evidence that estrogen receptor-1 (ESR1) mutations lead to resistance to AIs, the trial was modified into cohort 2, in which patients were randomly assigned to 1:1 palocoxib plus fulvestrant and Capecitabine group.
Experimental design flow chart.
Experimental design flow chart.
In cohort 2 [median PFS: 7.
KaplaneMeier curve of PFS.
KaplaneMeier curve of PFS.
However, the quality of life of patients treated with locoxib combined with ET was better (global health deterioration time HR=0.
It can be seen that compared with capecitabine, paloximab combined with endocrine therapy cannot improve the PFS of patients with MAC, but it can better improve the quality of life of patients.
references:
elsevier.
elsevier.
com/reader/sd/pii/S0923753420432211?token=CF65351F1C0C16BC1D794502AA684CD1D8FC285247BAD42DFB2020C0D47805E108F161D8DC435C11E7AF6E8ADC4D323D&originRegion=us-east-1&originCreation=20210412060802" target="_blank" rel="noopener">Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL.
Leave a message here
